Data and Safety Monitoring at the Helen Diller Family Comprehensive Cancer Center is overseen by a Data and Safety Monitoring Committee (DSMC), and conducted by a group of monitors and auditors within the Center. The DSMC and monitors are responsible for several activities related to the implementation of the Center's NCI-approved Data and Safety Monitoring Plan (DSMP). Data and Safety and Monitoring functions within the HDFCCC include 1) the conduct of internal audits of protocols;2) evaluation of the results of both internal and external audits of protocols, including those conducted by the NCI Cooperative Groups, other consortia, and CTEP;3) review and approval of any cohort dose escalation decisions on UCSF Institutional Phase I studies;4) review of interim analyses for institutional studies;5) evaluation and addressing of any concerns with regards to safety, or related study design and stopping rules, raised by principal investigators, site committees, the Protocol Review Committee (PRC), or Institutional Review Board (IRB);6) oversight of toxicity and Serious Adverse Events (SAEs) reported by each site committee;7) development and updating of the DSMP and guidelines for its use;8) communication of findings and recommendations with key stakeholders, including the PRC, IRB, and leadership of the Center;and 9) closure of studies for noncompliance or safety issues.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA082103-14
Application #
8388388
Study Section
Subcommittee G - Education (NCI)
Project Start
1999-08-05
Project End
2017-05-31
Budget Start
2012-09-19
Budget End
2013-05-31
Support Year
14
Fiscal Year
2012
Total Cost
$517,813
Indirect Cost
$187,118
Name
University of California San Francisco
Department
Type
DUNS #
094878337
City
San Francisco
State
CA
Country
United States
Zip Code
94143
Ryu, Jae Kyu; Rafalski, Victoria A; Meyer-Franke, Anke et al. (2018) Fibrin-targeting immunotherapy protects against neuroinflammation and neurodegeneration. Nat Immunol 19:1212-1223
Zhou, Yu; Zou, Hao; Yau, Christina et al. (2018) Discovery of internalizing antibodies to basal breast cancer cells. Protein Eng Des Sel 31:17-28
Tat, David; Kenfield, Stacey A; Cowan, Janet E et al. (2018) Milk and other dairy foods in relation to prostate cancer recurrence: Data from the cancer of the prostate strategic urologic research endeavor (CaPSUREā„¢). Prostate 78:32-39
Guydish, Joseph; Tajima, Barbara; Le, Thao et al. (2018) Do cigarette graphic warnings encourage smokers to attend a smoking cessation programme: a quasi-experimental study. Tob Control 27:43-49
Dvorak, Christopher C; Satwani, Prakash; Stieglitz, Elliot et al. (2018) Disease burden and conditioning regimens in ASCT1221, a randomized phase II trial in children with juvenile myelomonocytic leukemia: A Children's Oncology Group study. Pediatr Blood Cancer 65:e27034
Fan, Qi Wen; Nicolaides, Theodore P; Weiss, William A (2018) Inhibiting 4EBP1 in Glioblastoma. Clin Cancer Res 24:14-21
Sannino, Sara; Guerriero, Christopher J; Sabnis, Amit J et al. (2018) Compensatory increases of select proteostasis networks after Hsp70 inhibition in cancer cells. J Cell Sci 131:
Lam, Christine; Ferguson, Ian D; Mariano, Margarette C et al. (2018) Repurposing tofacitinib as an anti-myeloma therapeutic to reverse growth-promoting effects of the bone marrow microenvironment. Haematologica 103:1218-1228
Truillet, Charles; Parker, Matthew F L; Huynh, Loc T et al. (2018) Measuring glucocorticoid receptor expression in vivo with PET. Oncotarget 9:20399-20408
Phillips, Kathryn A; Trosman, Julia R; Deverka, Patricia A et al. (2018) Insurance coverage for genomic tests. Science 360:278-279

Showing the most recent 10 out of 192 publications